KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Short-Term Debt repayments (2019 - 2024)

Emergent BioSolutions' Short-Term Debt repayments history spans 4 years, with the latest figure at $222.7 million for Q3 2024.

  • For Q3 2024, Short-Term Debt repayments rose 471.03% year-over-year to $222.7 million; the TTM value through Jun 2025 reached $222.7 million, up 97.96%, while the annual FY2024 figure was $284.2 million, 28.74% down from the prior year.
  • Short-Term Debt repayments reached $222.7 million in Q3 2024 per EBS's latest filing, up from $56.5 million in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $353.0 million in Q3 2020 to a low of $5.0 million in Q1 2024.
  • Average Short-Term Debt repayments over 3 years is $132.0 million, with a median of $47.8 million recorded in 2023.
  • Peak YoY movement for Short-Term Debt repayments: surged 2253.33% in 2020, then crashed 83.76% in 2024.
  • A 3-year view of Short-Term Debt repayments shows it stood at $353.0 million in 2020, then plummeted by 96.6% to $12.0 million in 2023, then soared by 1755.83% to $222.7 million in 2024.
  • Per Business Quant, the three most recent readings for EBS's Short-Term Debt repayments are $222.7 million (Q3 2024), $56.5 million (Q2 2024), and $5.0 million (Q1 2024).